8-K 1 d8k.htm FORM 8-K Form 8-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): October 26, 2004

 

 

CuraGen Corporation

(Exact name of registrant as specified in its charter)

 

 

Delaware   0-23223   06-1331400

(State or other jurisdiction

of incorporation)

   (Commission File Number)  

(IRS Employer

Identification No.)

 

555 Long Wharf Drive, 11th Floor

New Haven, Connecticut 06511

(Address of principal executive offices) (Zip Code)

 

 

Registrant’s telephone number, including area code: (203) 401-3330

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Item 7.01. Regulation FD Disclosure.

 

On October 26, 2004, CuraGen Corporation and Bayer Pharmaceuticals Corporation announced that the companies have advanced a new orally active small molecule for the management of type 2 (adult-onset) diabetes into preclinical drug development. The collaboration between Bayer and CuraGen was established to identify and develop drugs targeted at the treatment of diabetes and obesity.

 

A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1, and is incorporated herein by reference.

 

Item 9.01. Financial Statements and Exhibits.

 

(c) The following exhibit is furnished with this report:

 

Exhibit

Number

  

Description

99.1   Press release of Registrant dated October 26, 2004.

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

   

CURAGEN CORPORATION

   

(Registrant)

Date: October 26, 2004

  

By:

  

/s/ David M. Wurzer

   

Name:

  

David M. Wurzer

   

Title:

  

Executive Vice President and

       

Chief Financial Officer